Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets

References

• Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA 2014; 111(34):12288-12293; PMID:25136130; http://dx.doi.org/10.1073/pnas.1402981111
   PubMed Web of Science ®Google Scholar
• Anderson RM, Donnelly CA, Gupta S. Vaccine design, evaluation, and community-based use for antigenically variable infectious agents. Lancet 1997; 350(9089):1466-1470; PMID:9371182; http://dx.doi.org/10.1016/S0140-6736(97)03255-8
   PubMed Web of Science ®Google Scholar
• Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol Immunother 2015; 64(1):99-104; PMID:25164877; http://dx.doi.org/10.1007/s00262-014-1599-7
   PubMed Web of Science ®Google Scholar
• Yu B, O'Toole SA, Trent RJ. Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr 2015; 4(2):125-138; PMID:26835368
   PubMedGoogle Scholar
• Reinherz EL, Keskin DB, Reinhold B. Forward Vaccinology: CTL Targeting Based upon Physical Detection of HLA-Bound Peptides. Front Immunol 2014; 5:418; PMID:25237310
   PubMed Web of Science ®Google Scholar
• Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyushniy O, Vittal V, et al. Proof of principle for epitope-focused vaccine design. Nature 2014; 507(7491):201-6; PMID:24499818; http://dx.doi.org/10.1038/nature12966
   PubMed Web of Science ®Google Scholar
• Kulp DW, Schief WR. Advances in structure-based vaccine design. Curr Opin Virol 2013; 3(3):322-31; PMID:23806515; http://dx.doi.org/10.1016/j.coviro.2013.05.010
   PubMed Web of Science ®Google Scholar
• Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones TC, Le NM, Pham QT, et al. Antibody landscapes after influenza virus infection or vaccination. Science 2014; 21;346(6212):996-1000; PMID:25414313; http://dx.doi.org/10.1126/science.1256427
   PubMed Web of Science ®Google Scholar
• Carlson JM, Le AQ, Shahid A, Brumme ZL. HIV-1 adaptation to HLA: a window into virus-host immune interactions. Trends Microbiol 2015; 23(4):212-24; PMID:25613992; http://dx.doi.org/10.1016/j.tim.2014.12.008
   PubMed Web of Science ®Google Scholar
• Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, Long J, Barrera J, Pena L, Grubman MJ, Nara PL. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008; 26:6189-6199; PMID:18852005; http://dx.doi.org/10.1016/j.vaccine.2008.09.080
   PubMed Web of Science ®Google Scholar
• Kissick HT, Sanda MG. The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Curr Opin Immunol 2015; 35:15-22; PMID:26050634; http://dx.doi.org/10.1016/j.coi.2015.05.004
   PubMed Web of Science ®Google Scholar
• Thomas S, Luxon BA. Vaccines based on structure-based design provide protection against infectious diseases. Expert Rev Vaccines 2013; 12(11):1301-11; PMID:24090172; http://dx.doi.org/10.1586/14760584.2013.840092
   PubMed Web of Science ®Google Scholar
• Cozzi R, Scarselli M, Ferlenghi I. Srtuctural vaccinology_ a three-dimensional view for vaccine development. Curr Top Med chem 2013; 13(20):2629-2637; PMID:24066888; http://dx.doi.org/10.2174/15680266113136660187
   PubMed Web of Science ®Google Scholar
• Wooldridge L, Ekeruche-Makinde J, van den Berg HA, Skowera A, Miles JJ, Tan MP, Dolton J, Clement M, Llewellyn-Lacey S, Price DA, et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem 2012; 287(2):1168-77; PMID:22102287; http://dx.doi.org/10.1074/jbc.M111.289488
   PubMed Web of Science ®Google Scholar
• Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol 2012; 12(9):669-77; PMID:22918468; http://dx.doi.org/10.1038/nri3279
   PubMed Web of Science ®Google Scholar
• Boesteanu A, Brehm M, Mylin LM, Christianson GJ, Tevethia SS, Roopenian DC, Joyce S. A molecular basis for how a single TCR interfaces multiple ligands. J Immunol 1998; 61(9):4719-27; PMID:NOT_FOUND
   PubMedGoogle Scholar
• Kim JH, Davis WG, Sambhara S, Jacob J. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc Natl Acad Sci U S A 2012; 109(34):13751-6; PMID:22869731; http://dx.doi.org/10.1073/pnas.0912458109
   PubMed Web of Science ®Google Scholar
• Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394:482-485; PMID:9697771
   PubMed Web of Science ®Google Scholar
• Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2(6):417-26
   PubMed Web of Science ®Google Scholar
• Che JW, Selin LK, Welsh RM. Evaluation of non-reciprocal heterologous immunity between unrelated viruses. Virology 2015; 482:89-97; PMID:25838115; http://dx.doi.org/10.1016/j.virol.2015.03.002
   PubMed Web of Science ®Google Scholar
• Simon M, Vanes L, Geahlen RL, Tybulewicz VL. Distinct roles for the linker region tyrosines of Syk in FcepsilonRI signaling in primary mast cells. J Biol Chem 2005; 280(6):4510-7; PMID:15576379; http://dx.doi.org/10.1074/jbc.M410326200
   PubMed Web of Science ®Google Scholar
• Bourdetsky D, Schmelzer CE, Admon A. The nature and extent of contributions by defective ribosome products to the HLA peptidome. Proc Natl Acad Sci U S A 2014; 111(16):E1591-9; PMID:24715725; http://dx.doi.org/10.1073/pnas.1321902111
   PubMed Web of Science ®Google Scholar
• Wei J, Gibbs JS, Hickman HD, Cush SS, Bennink JR, Yewdell JW. Ubiquitous Autofragmentation of Fluorescent Proteins Creates Abundant Defective Ribosomal Products (DRiPs) for Immunosurveillance. J Biol Chem 2015; 290(26):16431-9; PMID:25971973; http://dx.doi.org/10.1074/jbc.M115.658062
   PubMed Web of Science ®Google Scholar
• Chu Q, Ma J, Saghatelian A. Identification and characterization of sORF-encoded polypeptides. Crit Rev Biochem Mol Biol 2015; 50(2):134-41; PMID:25857697; http://dx.doi.org/10.3109/10409238.2015.1016215
   PubMed Web of Science ®Google Scholar
• Yewdell JW. To dream the impossible dream: universal influenza vaccination. Curr Opin Virol 2013; 3(3):316-21; PMID:23835048; http://dx.doi.org/10.1016/j.coviro.2013.05.008
   PubMed Web of Science ®Google Scholar
• Grant EJ, Chen L, Quiñones-Parra S, Pang K, Kedzierska K, Chen W. T-cell immunity to influenza A viruses. Crit Rev Immunol 2014; 34(1):15-39; PMID:24579700; http://dx.doi.org/10.1615/CritRevImmunol.2013010019
   PubMed Web of Science ®Google Scholar
• Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, Cho MW, Levin SA, Ndifon W, Wingreen NS. How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol 2010; 8(12):e1000571; PMID:21203586; http://dx.doi.org/10.1371/journal.pbio.1000571
   PubMed Web of Science ®Google Scholar
• Quiñones-Parra S, Grant E, Loh L, Nguyen TH, Campbell KA, Tong SY, Miller A, Doherty PC, Vijaykrishna D, Rossjohn J, et al. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc Natl Acad Sci U S A 2014; 111(3):1049-54; PMID:Can't; http://dx.doi.org/10.1073/pnas.1322229111
   PubMed Web of Science ®Google Scholar
• Bolton KJ, McCaw JM, Brown L, Jackson D, Kedzierska K, McVernon J. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control. PLoS One 2015; 10(3):e0120138; PMID:25811654; http://dx.doi.org/10.1371/journal.pone.0120138
   PubMed Web of Science ®Google Scholar
• Schwartzman LM, Cathcart AL, Pujanauski LM, Qi L, Kash JC, Taubenberger JK. An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. MBio 2015; 6(4):e01044; PMID:26199334; http://dx.doi.org/10.1128/mBio.01044-15
   PubMed Web of Science ®Google Scholar
• Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015; 349(6254):1301-6; PMID:26303961; http://dx.doi.org/10.1126/science.aac7263
   PubMed Web of Science ®Google Scholar
• Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan AC, Mercuri F, Rockman S, Chen W, Turner SJ, et al. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. MBio 2015; 6(6):e01024-15; PMID:26507227; http://dx.doi.org/10.1128/mBio.01024-15
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdjyorn S, Duangchinda T, Dong T, Rowland-Jones S, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9(7):921-7; PMID:12808447; http://dx.doi.org/10.1038/nm887
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014; 5:93; PMID:24639680; http://dx.doi.org/10.3389/fimmu.2014.00093
   PubMed Web of Science ®Google Scholar
• Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 11(8):532-43; PMID:21760609; http://dx.doi.org/10.1038/nri3014
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, MuhammadIsmail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373(13):1195-206; PMID:26214039; http://dx.doi.org/10.1056/NEJMoa1506223
   PubMed Web of Science ®Google Scholar
• Guy B, Jackson N. Dengue vaccine: hypothesis to understand CYD-TDV-induced protection. Nat Rev Microbiol 2016; 14(1):45-54; PMID:26639777; http://dx.doi.org/10.1038/nrmicro.2015.2
   PubMed Web of Science ®Google Scholar
• Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014; 40(1):13-24; PMID:24439265; http://dx.doi.org/10.1016/j.immuni.2013.12.010
   PubMed Web of Science ®Google Scholar
• Holz L, Rehermann B. T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res 2015; 114:96-105; PMID:25433310; http://dx.doi.org/10.1016/j.antiviral.2014.11.009
   PubMed Web of Science ®Google Scholar
• Nivarthi UK, Gras S, Kjer-Nielsen L, Berry R, Lucet IS, Miles JJ, Tracy SL, Purcell AW, Bowden DC, Hellard M, et al. An extensive antigenic footprint underpins immunodominant TCR adaptability against a hypervariable viral determinant. J Immunol 2014; 193(11):5402-13; PMID:25355921; http://dx.doi.org/10.4049/jimmunol.1401357
   PubMed Web of Science ®Google Scholar
• Ziegler S, Skibbe K, Walker A, Ke X, Heinemann FM, Heinold A, Mok JY, van Esch WY, Yang D, Wolfl M, et al. Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells. J Virol 2014; 88(19):11080-90; PMID:25008925; http://dx.doi.org/10.1128/JVI.01590-14
   PubMed Web of Science ®Google Scholar
• Esparza J. A new scientific paradigm may be needed to finally develop an HIV vaccine. Front Immunol 2015; 6:124; PMID:25852692; http://dx.doi.org/10.3389/fimmu.2015.00124
   PubMed Web of Science ®Google Scholar
• Haynes BF. New approaches to HIV vaccine development. Curr Opin Immunol 2015; 35:39-47; PMID:26056742; http://dx.doi.org/10.1016/j.coi.2015.05.007
   PubMed Web of Science ®Google Scholar
• Ndung'u T, Weiss RA. On HIV diversity. AIDS 2012; 26(10):1255-60; PMID:22706010; http://dx.doi.org/10.1097/QAD.0b013e32835461b5
   PubMed Web of Science ®Google Scholar
• McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2002; 2:283-291; PMID:12001999; http://dx.doi.org/10.1038/nri779
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-645; PMID:19242411; http://dx.doi.org/10.1038/nature07746
   PubMed Web of Science ®Google Scholar
• Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012; 63:95-111; PMID:21942424; http://dx.doi.org/10.1146/annurev-med-042010-085643
   PubMed Web of Science ®Google Scholar
• Adnan S, Colantonio AD, Yu Y, Gillis J, Wong FE, Becker EA, Piatak M Jr, Reeves RK, Lifson JD, O'Connor SL, et al. CD8 T cell response maturation defined by anentropic specificity and repertoire depth correlates with SIVΔnef-induced protection. PLoS Pathog 2015; 11(2):e1004633; PMID:25688559; http://dx.doi.org/10.1371/journal.ppat.1004633
   PubMed Web of Science ®Google Scholar
• Julien JP, Lee PS, Wilson IA. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev 2012; 250(1):180-98; PMID:23046130; http://dx.doi.org/10.1111/imr.12005
   PubMed Web of Science ®Google Scholar
• Jones NG, DeCamp A, Gilbert P, Peterson ML, Gurwith M, Cao H. AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 2009; 27:1136-1140; PMID:19071176; http://dx.doi.org/10.1016/j.vaccine.2008.11.071
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893; PMID:19012954; http://dx.doi.org/10.1016/S0140-6736(08)61591-3
   PubMed Web of Science ®Google Scholar
• Esparza J, Van Regenmortel MH. More Surprises in the Development of an HIV Vaccine. Front Immunol 2014; 5:329; PMID:25071786; http://dx.doi.org/10.3389/fimmu.2014.00329
   PubMed Web of Science ®Google Scholar
• Singh RA, Rodgers JR, Barry MA. The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol 2002; 169:6779-6786; PMID:12471109; http://dx.doi.org/10.4049/jimmunol.169.12.6779
   PubMed Web of Science ®Google Scholar
• Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33(4):530-541; PMID:21029963; http://dx.doi.org/10.1016/j.immuni.2010.09.017
   PubMed Web of Science ®Google Scholar
• Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, Kod PD, Thinnes TC, Bhullar D, Briney B, et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline targeting immunogen. Science 2015; 349(6244):156-61; PMID:26089355; http://dx.doi.org/10.1126/science.aac5894
   PubMed Web of Science ®Google Scholar
• Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015; 349(6244):aac4223; PMID:26089353; http://dx.doi.org/10.1126/science.aac4223
   PubMed Web of Science ®Google Scholar
• Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig Knockin Mice. Cell 2015; 161(7):1505-15; PMID:26091035; http://dx.doi.org/10.1016/j.cell.2015.06.003
   PubMed Web of Science ®Google Scholar
• Mascola JR. HIV. The modern era of HIV-1 vaccine development. Science 2015; 349(6244):139-40; PMID:26160931; http://dx.doi.org/10.1126/science.aac7800
   PubMed Web of Science ®Google Scholar
• Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE, Shields JL, Perry J, lavine CL, Cheung A, Ellingson-Strouss K, et al. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol 2015; 89(5):2507-19; PMID:NOT_FOUND; http://dx.doi.org/10.1128/JVI.03331-14
   PubMed Web of Science ®Google Scholar
• Van Regenmortel MH. An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine. Front Immunol 2014; 5:593; PMID:25477882
   PubMed Web of Science ®Google Scholar
• Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med 2015; 21(11):1332-6; PMID:26457756; http://dx.doi.org/10.1038/nm.3963
   PubMed Web of Science ®Google Scholar
• Anderson DE, Singapuri A, Kang KH, Montefiori DC, Torres JV. Timing of retroviral infection influences anamnestic immune response in vaccinated primates. Viral Immunol 2005; 18:689-694; PMID:16359235; http://dx.doi.org/10.1089/vim.2005.18.689
   PubMed Web of Science ®Google Scholar
• Hewer R, Meyer D. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol Immunol 2003; 40:327-335; PMID:14522014; http://dx.doi.org/10.1016/S0161-5890(03)00163-9
   PubMed Web of Science ®Google Scholar
• Oliveira E, Jimenez-Clavero MA, Nunez JI, Sobrino F, Andreu D. Analysis of the immune response against mixotope peptide libraries from a main antigenic site of foot-and-mouth disease virus. Vaccine 2005; 23:2647-2657; PMID:15780448; http://dx.doi.org/10.1016/j.vaccine.2004.10.041
   PubMed Web of Science ®Google Scholar
• Azizi A, Anderson DE, Torres JV, Ogrel A, Ghorbani M, Soare C, Sandstrom P, Fournier J, Diaz-Mitoma F. Induction of broad cross-subtypespecific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol 2008; 180:2174-2186; PMID:18250424; http://dx.doi.org/10.4049/jimmunol.180.4.2174
   PubMed Web of Science ®Google Scholar
• Pedroza-Roldan C, Charles-Niño C, Saavedra R, Govezensky T, Vaca L, Avaniss-Aghajani E, Gevorkian G, Manoutcharian K. Variable epitope library-based vaccines: shooting moving targets. Mol Immunol 2009; 47(2–3):270-82; PMID:19853920; http://dx.doi.org/10.1016/j.molimm.2009.09.024
   PubMed Web of Science ®Google Scholar
• Charles-Niño C, Pedroza-Roldan C, Viveros M, Gevorkian G, Manoutcharian K. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. Vaccine 2011; 29(32):5313-21; PMID:Can't; http://dx.doi.org/10.1016/j.vaccine.2011.05.007
   PubMed Web of Science ®Google Scholar
• Fomsgaard A, Nielsen HV, Bryder K, Machuca R, Bruun L, Hansen J, Buus S. Improved humoral and cellular immune responses against the 120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen. Scand J Immunol 1998; 47:289-295; PMID:9600309; http://dx.doi.org/10.1046/j.1365-3083.1998.00323.x
   PubMed Web of Science ®Google Scholar
• Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 2008; 381(2):251-260; PMID:18822440; http://dx.doi.org/10.1016/j.virol.2008.08.032
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Sharpe Cohen S, Krachmarov C, Wang S, Pinter A, Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp envelope. Virology 2008; 372:233-246.70; PMID:18061228; http://dx.doi.org/10.1016/j.virol.2007.09.024
   PubMed Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014; 11(9):509-24; PMID:25001465; http://dx.doi.org/10.1038/nrclinonc.2014.111
   PubMed Web of Science ®Google Scholar
• Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Immunotherapy in cancer: A combat between tumors and the immune system; you win some, you lose some. Front Immunol 2015; 6:127; PMID:25859247
   PubMed Web of Science ®Google Scholar
• Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, Bakal C, Yuan Y. Microenvironmental heterogeneity parallels breast cancer progression: A histology-genomic integration analysis. PLoS Med 2016; 13(2):e1001961; PMID:26881778; http://dx.doi.org/10.1371/journal.pmed.1001961
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27:16-25; PMID:24531241; http://dx.doi.org/10.1016/j.coi.2014.01.004
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. How does multistep tumorigenesis really proceed? Cancer Discov 2015; 5(1):22-4; PMID:25583800; http://dx.doi.org/10.1158/2159-8290.CD-14-0788
   PubMed Web of Science ®Google Scholar
• Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15(8):457-72; PMID:26205340; http://dx.doi.org/10.1038/nrc3973
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J 2013; 32(2):194-203; PMID:23258224; http://dx.doi.org/10.1038/emboj.2012.333
   PubMed Web of Science ®Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 2015; 125(9):3413-21; PMID:26258412; http://dx.doi.org/10.1172/JCI80008
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515(7528):577-81; PMID:25428507; http://dx.doi.org/10.1038/nature13988
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Maio M, Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol 2015; 42(3):429-35; PMID:25965361; http://dx.doi.org/10.1053/j.seminoncol.2015.02.010
   PubMed Web of Science ®Google Scholar
• Desrichard A, Snyder A, Chan TA. Cancer Neoantigens and Applications for Immunotherapy. Clin Cancer Res 2016; 22(4):807-12. DOI: 10.1158/1078-0432.CCR-14-3175.82
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19(6):747-52; PMID:23644516; http://dx.doi.org/10.1158/1078-0432.CCR-14-3175
   PubMed Web of Science ®Google Scholar
• van Buuren MM, Calis JJ, Schumacher TN. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology 2014; 3:e28836; PMID:25083320; http://dx.doi.org/10.4161/onci.28836
   PubMed Web of Science ®Google Scholar
• Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 2014; 20(13):3401-10; PMID:24987109; http://dx.doi.org/10.1158/1078-0432.CCR-14-0433
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Neiller C, Shinde J, Soysouvanh F, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47(5):505-11; PMID:25822088; http://dx.doi.org/10.1038/ng.3252
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348(6236):803-8; PMID:25837513; http://dx.doi.org/10.1126/science.aaa3828
   PubMed Web of Science ®Google Scholar
• Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS. Immune responses to human tumors: development of tumor vaccines. Anticancer Res 2003; 23(3A):1969-96; PMID:12894571
   PubMed Web of Science ®Google Scholar
• Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A 2010; 107(10):4652-7; PMID:20133772; http://dx.doi.org/10.1073/pnas.0914879107
   PubMed Web of Science ®Google Scholar
• Hoppes R, Oostvogels R, Luimstra JJ, Wals K, Toebes M, Bies L, Ekkebus R, Rijal P, Celie PH, Huang JH, et al. Altered peptide ligands revisited: vaccine design through chemically modified HLA- A2-restricted T cell epitopes. J Immunol 2014; 193(10):4803-13; PMID:25311806; http://dx.doi.org/10.4049/jimmunol.1400800
   PubMed Web of Science ®Google Scholar
• Abdul-Alim CS, Li Y, Yee C. Conditional superagonist CTL ligands for the promotion of tumor- specific CTL responses. J Immunol 2010; 184(11):6514-21; PMID:20483791; http://dx.doi.org/10.4049/jimmunol.0900448
   PubMed Web of Science ®Google Scholar
• Ekeruche-Makinde J, Clement M, Cole DK, Edwards ES, Ladell K, Miles JJ, Mattews KK, Fuller A, Lloyd KA, Madura F, et al. T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J Biol Chem 2012; 287(44):37269-81; PMID:22952231; http://dx.doi.org/10.1074/jbc.M112.386409
   PubMed Web of Science ®Google Scholar
• Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE. Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor- specific T cell receptor. J Biol Chem 2013; 288(46):33213-25; PMID:24106273; http://dx.doi.org/10.1074/jbc.M113.509554
   PubMed Web of Science ®Google Scholar
• Suresh K, Scheid E, Klotz L, Venkateswaran V, Gauldie J, Foley R. Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2. Int J Oncol 2011; 39(4):907-13; PMID:21769423
   PubMed Web of Science ®Google Scholar
• Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Ostapenko V, Schijns V. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?. Vaccine 2014; 32(32):4015-24; PMID:24837511; http://dx.doi.org/10.1016/j.vaccine.2014.05.006
   PubMed Web of Science ®Google Scholar
• Milani A, Sangiolo D, Aglietta M, Valabrega G. Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press) 2014; 6:159-68; PMID:25339848; http://dx.doi.org/10.2147/BCTT.S38428
   PubMedGoogle Scholar
• Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitgovel L, Kroemer G, et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology 2015; 4(4):e974411; PMID:26137405; http://dx.doi.org/10.4161/2162402X.2014.974411
   PubMed Web of Science ®Google Scholar
• Cody JJ, Hurst DR. Promising oncolytic agents for metastasis breast cancer treatment. Oncolytic Virotherapy 2015; 4:63-73; PMID:NOT_FOUND
   PubMedGoogle Scholar
• Sokolowski NAS, Rizos H, Diefenbach RJ. Oncolytic virotherapy using herpes simplexvirus: how far have we come?. Oncolytic Virotherapy 2015; 4:207-219; PMID:NOT_FOUND
   PubMedGoogle Scholar
• Pieczonka CM, Telonis D, Mouraviev V, Albala D. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: considerations for clinical practice. Rev Urol 2015; 17(4):203-10; PMID:26839517
   PubMedGoogle Scholar
• Bourzac K. An immune one-two punch. Nature 2015; 528(7582):S134-6; PMID:26672788; http://dx.doi.org/10.1038/528S134a
   PubMed Web of Science ®Google Scholar
• Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Rationale for a multimodality strategy to enhance the efficacy of dendritic cell-based cáncer immunotherapy. Front Immunol 2015; 6:271; PMID:26082780; http://dx.doi.org/10.3389/fimmu.2015.00271
   PubMed Web of Science ®Google Scholar
• Gulley JL. Therapeutic vaccines: the ultimate personalized therapy?. Hum Vaccin Immunother 2013; 9(1):219-21; PMID:22995839; http://dx.doi.org/10.4161/hv.22106
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Buque A, Eggermont A, Cremer I, Sautes-Fridman C, Galon J, Tartour E, Zitgovel L, Kroemer G, et al. Trial watch: peptide-based anticancer vaccines. Oncoimmunology 2015; 4(4):e974411; PMID:26137405; http://dx.doi.org/10.4161/2162402X.2014.974411
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive nonsmall-cell lung cáncer (MAGRIT): a randomized-double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17(6): 822–835; http://dx.doi.org/10.1016/S1470-2045(16)00099-1
   Web of Science ®Google Scholar
• Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cáncer vaccine. Semin Cancer Biol 2003; 13(6):401-7; PMID:15001158; http://dx.doi.org/10.1016/j.semcancer.2003.09.003
   PubMed Web of Science ®Google Scholar
• Kelland L. Discontinued drugs in 2005: oncology drugs. Expert Opin Investig Drugs 2006; 15(11):1309-18; PMID:17040193; http://dx.doi.org/10.1517/13543784.15.11.1309
   PubMed Web of Science ®Google Scholar
• Noe Dominguez-Romero A, Zamora-Alvarado R, Servín-Blanco R, Pérez-Hernández EG, Castrillon-Rivera LE, Munguia ME, Acero G, Govezensky T, Gevorkian G, Manoutcharian K. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. Hum Vaccin Immunother 2014; 10(11):3201-13; PMID:25483665; http://dx.doi.org/10.4161/hv.29679
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignel GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-421; PMID:23945592; http://dx.doi.org/10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, et al. Ra´pid and long-term immunity elicited by DNA encoded antibodu prophylaxis and DNA vaccination against Chikungunya virus. J Infect Dis 2016; PMID:27001960; http://dx.doi.org/10.1093/infdis/jiw111
   PubMed Web of Science ®Google Scholar